TY - JOUR
T1 - Long-acting HIV drugs for treatment and prevention
AU - Gulick, Roy M.
AU - Flexner, Charles
N1 - Funding Information:
R.M.G. is not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review. C.F. reports serving as a paid consultant for Cipla Pharmaceuticals, Janssen Pharmaceuticals, Merck Laboratories, Mylan Pharmaceuticals, and ViiV Healthcare, and received research grant support from Gilead Sciences paid to his university.
Publisher Copyright:
© 2019 by Annual Reviews.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/1/27
Y1 - 2019/1/27
N2 - Antiretroviral drugs have revolutionized the treatment and prevention of HIV infection; however, adherence is critical for sustained efficacy. Current HIV treatment consists of three-drug regimens, and current HIV pre-exposure prophylaxis (PrEP) consists of a two-drug regimen; both generally require adherence to once-daily dosing. Long-acting formulations are useful in the treatment and prevention of other conditions (e.g., contraceptives, antipsychotics) and help promote adherence. Newer long-acting formulations of approved and investigational antiretroviral drugs in existing and newer mechanistic classes are under study for HIV treatment and prevention, including some phase III trials. Although long-acting antiretroviral drugs hold promise, some clinical challenges exist, including managing side effects, drug-drug interactions, pregnancy, and long-lasting drug concentrations that could lead to the development of drug resistance. This review aims to summarize currently available information on long-acting antiretroviral drugs for HIV treatment and prevention.
AB - Antiretroviral drugs have revolutionized the treatment and prevention of HIV infection; however, adherence is critical for sustained efficacy. Current HIV treatment consists of three-drug regimens, and current HIV pre-exposure prophylaxis (PrEP) consists of a two-drug regimen; both generally require adherence to once-daily dosing. Long-acting formulations are useful in the treatment and prevention of other conditions (e.g., contraceptives, antipsychotics) and help promote adherence. Newer long-acting formulations of approved and investigational antiretroviral drugs in existing and newer mechanistic classes are under study for HIV treatment and prevention, including some phase III trials. Although long-acting antiretroviral drugs hold promise, some clinical challenges exist, including managing side effects, drug-drug interactions, pregnancy, and long-lasting drug concentrations that could lead to the development of drug resistance. This review aims to summarize currently available information on long-acting antiretroviral drugs for HIV treatment and prevention.
KW - HIV
KW - antiretroviral drugs
KW - extended-release
KW - implants
KW - long-acting
KW - monoclonal antibodies
UR - http://www.scopus.com/inward/record.url?scp=85060583710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060583710&partnerID=8YFLogxK
U2 - 10.1146/annurev-med-041217-013717
DO - 10.1146/annurev-med-041217-013717
M3 - Review article
C2 - 30355266
AN - SCOPUS:85060583710
SN - 0066-4219
VL - 70
SP - 137
EP - 150
JO - Annual review of medicine
JF - Annual review of medicine
ER -